Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy. Farmeconomia. Health economics and therapeutic pathways, [S. l.], v. 17, n. 3, 2016. DOI: 10.7175/fe.v17i3.1264. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/1264. Acesso em: 29 oct. 2025.